Status:
COMPLETED
Maintaining Nonsmoking
Lead Sponsor:
University of California, San Francisco
Collaborating Sponsors:
National Institute on Drug Abuse (NIDA)
Pfizer
Conditions:
Nicotine Dependence
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
The research is based on a chronic disorder model of cigarette smoking which suggests that long-term treatment targeted to prevent relapse may be useful. Based on this model, the investigators have de...
Detailed Description
This study will test a series of hypotheses comparing the efficacy of the relapse prevention treatment to other extended treatments. All participants will be assessed at baseline on demographics, smok...
Eligibility Criteria
Inclusion
- At least 18 years of age
- Must be smoking 5 or more cigarettes per day
Exclusion
- Previous history of bipolar/manic-depressive disorder
- Current diagnosis of schizophrenia
- Acute life threatening diseases
- Evidence of alcohol or other drug abuse so severe that the patient is judged to be potentially unable to comply with the protocol
- Pregnancy or lactation
- Individuals with out of normal range blood pressure, active angina, valve disease, valve replacement, active cardiomyopathies, myocardial infarction or Coronary artery bypass grafting (CABG) within one year, and Congestive heart failure (CHF)
Key Trial Info
Start Date :
May 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2016
Estimated Enrollment :
216 Patients enrolled
Trial Details
Trial ID
NCT01162239
Start Date
May 1 2010
End Date
June 1 2016
Last Update
November 12 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of California San Francisco
San Francisco, California, United States, 94143